Your Health, We Care
Release date: 2024-08-07 17:46:16 Recommended: 119
Capmatinib can be used to treat patients with METex14-mutated non-small cell lung cancer and is a targeted drug manufactured by Novartis Pharmaceuticals.
Before following the doctor's instructions to purchase and use the drug, the patient should have an understanding of the dosage of the drug, which is organized as follows:
The recommended dose of capmatinib is 400 mg orally twice daily. The medication can be taken before or after meals without special adjustments. Tablets should be swallowed whole, avoiding breaking, crushing, or chewing. If you miss a dose or vomit after taking the medicine, you do not need to make up the dose, and you can take the next dose as scheduled at the next dose.
When patients experience adverse reactions, the dose of capmatinib should be adjusted on a case-by-case basis. The first dose adjustment recommends reducing the dose to 300 mg twice daily; If the reaction persists, it can be further reduced to 200 mg twice daily. If the patient is unable to tolerate a dose of 200 mg, permanent discontinuation of the drug should be considered.
According to the drug label, the drug interactions of capmatinib mainly include the following:
CYP3A is an important drug-metabolizing enzyme in the human body and is involved in the metabolic process of a variety of drugs. When capmatinib is used concomitantly with strong CYP3A inhibitors (such as itraconazole, ketoconazole, voriconazole, atazanavir, ritonavir, clarithromycin, and grapefruit), these inhibitors significantly reduce the activity of CYP3A, resulting in a slowdown in the metabolism of capmatinib in the body and an abnormal increase in blood concentration.
This condition may trigger a series of serious adverse effects, including but not limited to cardiotoxicity, liver damage, neurological abnormalities, etc. In order to avoid these potential risks, the concomitant use of capmatinib with strong inhibitors of CYP3A should be strictly avoided in clinical practice.
In contrast to strong CYP3A inhibitors, CYP3A inducers (such as rifampicin, rifapentine, phenytoin, carbamazepine, barbiturates, St. John's wort, etc.) can enhance CYP3A activity and promote drug metabolism.
When capmatinib is used simultaneously with these inducers, the rate of metabolism of capmatinib is accelerated, resulting in a decrease in effective concentrations in the body and a decrease in antitumor activity. This may weaken the therapeutic effect of capmatinib or even lead to treatment failure. Concomitant use of capmatinib with CYP3A inducers should also be avoided.
[Warm Tips] The medicine should be stored in a dark, sealed and dry environment to ensure that the medicine remains stable during the expiration date.
